Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Successful Innovation in B2B Takes Bringing the Whole Company to the Table

Successful B2B innovation demands cross-functional alignment, a critical factor often overlooked. True innovation requires a disciplined, strategic approach beyond mere brainstorming. Integrating teams across a company can facilitate meaningful and sustainable innovation.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Gerry Mecca · B2b CompaniesEkg GroupGerry MeccaGo-to-market Strategies
Share

Key takeaways

01

Cross-functional alignment is essential for B2B innovation.

02

Discipline and strategy are necessary for true innovation.

03

Integrating company teams leads to sustainable innovation.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In the realm of business, the term 'innovation' is often tossed around like a shiny buzzword, suggesting a world of limitless possibilities and creative experimentation. Especially when tackling innovation in B2B, though, whether in the form of new business models, products, services, or partnerships, true innovation requires far more than mere brainstorming and ideation; it demands a disciplined and strategic approach to transform ideas into tangible, profitable outcomes.

Innovation in B2B takes many forms. In healthcare, digital innovation is creating new competitive edges for medtech and solutions providers as digital payments and AI sweep the industry. Digital transformation is also opening new doors in B2B; companies across industry are seeing value with innovation in B2B that makes embedded analytics a strategic priority and a transformation agent for operations, new services, financial efficacy, and more. Some thought leaders put the emphasis on media strategies being the chief battleground for innovation as B2B works to catch up to B2C and adopt innovative digital marketing strategies.

What really makes for a successful strategy for innovation in B2B, though? Regardless of the market or technology in question, organizational culture that fosters unedited and free-flowing ideas, yet couples this creativity with rigorous mechanisms to ensure these ideas are more than just fleeting thoughts, is the bedrock of any successful mission of innovation in B2B companies. Gerry Mecca, a cutting-edge senior leader in technology and Principal at The EKG Group, shares some of his strategies for making good on promises of innovation, pulling from his 40+ years working in the technology and CPG sectors and consulting businesses on their executive technology strategies.

"I always think of the example of penicillin was invented somewhat accidentally, then innovated once so that it could be taken on to the field in military applications. But the real innovation was when it was made into a pill that people could take. Each of those steps were innovations," Mecca said. "None of those steps would have taken place if somebody didn't sit down and say, here's what we could do or what do you think about this? Get a bunch of smart people together, get them to have a little bit of money to make their innovations become more than just a piece of paper."

Get a bunch of smart people together, get them to have a little bit of money to make their innovations become more than just a piece of paper.
— Gerry Mecca, Principal at The EKG Group

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Gerry Mecca
Gerry MeccaGlobal Chief Information Officer

Cutting-edge Senior Leader whose technology solutions and business acumen have enabled startups as well as established global companies to grow and thrive in highly competitive markets like IngramMicro, Applied Creative Technology, ConocoPhillips, Dr Pepper, Cadbury, Keurig, Datascan, and Tropicana. Works across organizations to develop, communicate and sell an innovative technology vision that drives companies forward.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

Gerry Mecca
Gerry Mecca

Global Chief Information Officer

Cutting-edge Senior Leader whose technology solutions and business acumen have enabled startups as well as established global companies to grow and thrive in highly competitive markets like IngramMicro, Applied Creative Technology, ConocoPhillips, Dr Pepper, Cadbury, Keurig, Datascan, and Tropicana. Works across organizations to develop, communicate and sell an innovative technology vision that drives companies forward.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512